Zidovudine

Excreted Unchanged %
8-25
Half-Life (Normalesrd) Hours
1.1-1.4/1.4-3
Plasma Protein Binding %
10-30
Volume Of Distribution L/Kg
1.4-3
Dose For Normal Renal Function
200 mg q8h
Second Dose
Second Dose: 300 mg q12h
Adjustment For Renal Failure Method
D, I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100 mg q8h [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose for GFR <10
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100%, [B]
References
Deray G, Diquet B, Martinez F, Vidal AM, Petitclerc T, Ben Hmida M, et al. Pharmacokinetics of zidovudine in a patient on maintenance hemodialysis [Letter]. N Engl J Med. 1988; 319: 1606-7. [PMID: 3200272] / Gallicano KD, Tobe S, Sahai J, McGilveray IJ, Cameron DW, Kriger F, et al. Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). J Acquir Immune Defic Syndr. 1992; 5: 242-50. [PMID: 1740749] / Gleason J, Brier ME. Zidovudine: therapeutic recommendations for its use in renal failure. Semin Dial. 1990; 3: 101-4. [PMID unavailable] / Klecker RW Jr, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3&#146; -azido-3&#146; -deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987; 41: 407-12. [PMID: 3549120] / Kremer D, Munar MY, Kohlhepp SJ, Swan SK, Stinnett EA, Gilbert DN, et al. Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. Pharmacotherapy. 1992; 12: 56-60. [PMID: 1549540] / Singlas E, Pioger JC, Taburet AM, Colin JN, Fillastre JP. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther. 1989; 46: 190-7. [PMID: 2758728] / Tartaglione TA, Holeman E, Opheim K, Smith T, Collier AC. Zidovudine disposition during hemodialysis in a patient with acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1990; 3: 32-4. [PMID: 2293640]
Toxicity Notes
Enormous interpatient variation. Metabolite renally excreted.